Pacific Biosciences Of California (PACB) Notes Payables (2011 - 2022)

Pacific Biosciences Of California has reported Notes Payables for 7 years, with the latest figure at $1.8 million in Q4 2022.

• On a quarterly basis, Notes Payables rose 14.55% year-over-year to $1.8 million in Q4 2022; TTM through Dec 2022 was $1.8 million, a 14.55% increase from a year earlier, with the FY2022 full-year figure at $1.8 million, up 14.55% from the prior year.
• Notes Payables was $1.8 million for Q4 2022 at Pacific Biosciences Of California, up from $1.6 million in the prior quarter.
• The five-year high for Notes Payables was $15.9 million in Q4 2019, with the low at $1.6 million in Q4 2021.
• Average Notes Payables over 3 years is $10.8 million, with a median of $15.1 million recorded in 2019.
• The largest YoY upside for Notes Payables was 14.55% in 2022 against a maximum downside of 14.55% in 2022.
• Over 3 years, Notes Payables stood at $15.9 million in 2019, then sank by 89.87% to $1.6 million in 2021, then advanced by 14.55% to $1.8 million in 2022.
• The last three Notes Payables figures came in at $1.8 million (Q4 2022), $1.6 million (Q4 2021), and $15.9 million (Q4 2019), per Business Quant data.